Novo Nordisk 10 Year Ambition for
|
|
- Amberlynn Todd
- 5 years ago
- Views:
Transcription
1 Novo Nordisk 10 Year Ambition for Obesity disease: pathophysiology, Obesity consequences and management beyond weight loss significantly opened up the market by specifically addressing barriers across stakeholders Obesity will be widely recognised as a chronic disease Within 10 years Novo Nordisk will have a loss efficacy R. Medlej, 2018% weight
2 GLP-1 is a physiological regulator of appetite and energy intake Obesity is a chronic disease requiring long-term management GLP-1 is a physiological regulator of appetite and energy intake Liraglutide, a once-daily human GLP-1 analogue, reduces appetite and energy intake Efficacy and safety of liraglutide 3.0 mg in weight management GLP-1, glucagon-like peptide-1
3 Definition of obesity Obesity is defined as abnormal or excessive fat accumulation that may impair health Body mass index (BMI) provides the most convenient populationlevel measure of overweight and obesity currently available weight (kg) BMI = height (m 2 ) Classification BMI (kg/m 2 ) Underweight <18.5 Normal range 18.5 and <25 Overweight 25 and <30 Obesity 30 Obesity class I 30 and <35 Obesity class II 35 and <40 Obesity class III 40 WHO. Factsheet
4 Control of Energy Metabolism COGNITIVE REPONSE Afferent Signals Neural Hormones Nutrients CENTRAL CONTROL HYPOTHALAMUS Neurotransmitters Neuropeptides Efferent Signals Autonomic nervous system Adipose tissue Pancreas Gut Peripheral Organs
5 MOLECULES IMPLICATED IN ENEGY METABOLISM Appetite NPY Agouti-related protein Ghréline Noradrénaline (α 2) Opioïdes Endocanabinoides (CB1-R) Appetite - Leptine - POMC,α MSH (MC4-R) Serotonin Dopamine CCK GLP-1 PYY 3-36 Insulin Glucose, FFA..
6 Obesity is a complex and multifactorial disease with multiple pathophysiologic origins Environmental Epigenetic Genetic 40-70% Obesity Sociocultural Physiologic Behavioral Bray GA, et al. Lancet. 2016;387:
7 Obesity is a complex and multifactorial disease Energy intake Energy expenditure Mesolymbic (reward)system Dopamine, Serotonine, Endocanabinoides Hedonic input Experienced palatability or pleasure Environment Inactive lifestyle, smoking cessation, psychosocial factors Genetics Medications 1. Badman, Flier. Science 2005;307: ; 2. US Department of Health and Human Services, NIH Publication No
8 Age-standardized prevalence of obesity: Men Women In Lebanon,The prevalence of obesity is 31%2 Prevalence of Obesity < Values for prevalence are provided as decimals 1.GBD 2015 Obesity Collaborators N Engl J Med 2017 Jun 12 [Epub ahead of print] 2. The World Factbook, retrieved from on July 24, >0.35
9 Obesity is recognised as a disease and health issue WOF The World Obesity Federation takes the position that obesity is a chronic, relapsing, progressive disease process and emphasizes the need for immediate action for prevention and control of this global epidemic 1 CON Obesity is characterized by excess body fat that can threaten or affect your health. Many organizations including the Canadian Obesity Network, now consider obesity to be a chronic disease. 4 AMA World Obesity Federation American Medical Association recognizes obesity and overweight as a chronic medical condition (de facto disease state) and urgent public health problem and work towards the recognition of obesity intervention as an essential medical service 2 American Medical Association EASO Canadian Obesity Network A progressive disease, impacting severely on individuals and society alike, it is widely acknowledged that obesity is the gateway to many other disease areas 5 European Association for the Study of Obesity FDA Obesity is a chronic relapsing health risk defined by excess body fat 3 The US Food and Drug Administration EMA Obesity is recognised as a chronic clinical condition and is considered to be the result of interactions of genetic, metabolic, environmental and behavioural factors, and is associated with increases in both morbidity and mortality 6 European Medicines Agency Bray et al. Obes Rev 2017;18:715 23; 2. AMA resolutions. June Available here; 3. Food and Drug Administration. Guidance for Industry Developing Products for Weight Management 2007 Available here; 4. Canadian Obesity Network. Available here; 5. EASO: 2015 Milan Declaration: A Call to Action on Obesity. Available here; 6. EMA Draft Guideline on clinical evaluation of medicinal products used in weight control EMA/CHMP/311805/2014. Available here.
10 Life expectancy decreases as BMI increases Proportion still alive (%) BMI range (kg/m 2 ) Normal BMI = almost 80% chance of reaching age 70 BMI = ~60% chance of reaching age 70 BMI = ~50% chance of reaching age 70 Age (years)
11 Obesity is associated with multiple comorbidities Metabolic, Mechanical and Mental Metabolic Mechanical Mental Mental health Depression Anxiety Asthma Fatty liver 3 Sleep Apnoea Cardiovascular diseases Stroke Dyslipidaemia Hypertension Coronary artery disease Coronary heart failure Pulmonary embolism Cancers* Physical functioning Gallstones Infertility Incontinence Arthrosis Chronic back pain Type 2 diabetes Prediabetes Thrombosis Gout *Including breast, colorectal, endometrial, esophageal, kidney, ovarian, pancreatic and prostate Adapted from Sharma AM. Obes Rev. 2010;11:808-9; Guh et al. BMC Public Health 2009;9:88; Luppino et al. Arch Gen Psychiatry 2010;67:220 9; Simon et al. Arch Gen Psychiatry 2006;63:824 30; Church et al. Gastroenterology 2006;130: ; Li et al. Prev Med 2010;51:18 23; Hosler. Prev Chronic Dis 2009;6:A48
12 Insulin Resistance AngioTNG Leptin Adiponectin TNF α FFA Stroke
13 Cancer It is estimated that obesity accounts for ~ 20% of all cancer cases. In a large review obesity was the cause of a quarter to onethird of cancers of the colon, breast, endometrium, kidney and oesophagus. It is also associated with increased risk of gastric, pancreatic, gallbladder cancer, as well as leukaemia. Furthermore, prognosis is poorer in obese individuals who develop some cancer types. Weight loss has been shown to reduce the risk of some cancers including breast cancer, particularly among postmenopausal women.
14
15 NAFLD & NASH Non-alcoholic fatty liver disease (NAFLD) is now the commonest cause of chronic liver disease worldwide, estimated to be present in 20 35% of adults in the developed world. One-third of these cases progress to non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma. Risk of NAFLD is strongly correlated with BMI. (steatosis found in 15% in non-obese persons, 65% in people with Class I or II obesity and 85% in Class III obesity). Weight loss is the best treatment for NAFLD with studies showing bariatric surgery-induced weight loss leading to resolution of NASH in 80% of cases.
16 Weight loss leads to improvement of many obesity related comorbidities Benefits of 5 10% weight loss Reduction in risk of type 2 diabetes 1 Reduction in CV mortality 2 Improvements in blood lipid profile 3 Improvements in blood pressure 4 Improvements in severity of obstructive sleep apnoea 5,6 Improvements in health-related quality of life 7,8 1. Knowler et al. N Engl J Med 2002;346: ; 2. Li et al. Lancet Diabetes Endocrinol 2014;2:474 80; 3. Datillo et al. Am J Clin Nutr 1992;56:320 8; 4. Wing et al. Diabetes Care 2011;34:1481 6; 5. Foster et al. Arch Intern Med 2009;169: ; 6. Kuna et al. Sleep 2013;36:641 9; 7. Warkentin et al. Obes Rev 2014;15:169 82; 8. Wright et al. J Health Psychol 2013;18:574 86
17 Maintenance of weight loss is challenging 5 Anderson et al. Foster et al. Graham et al. Hensrud et al. Jordan et al. Kramer et al. Lantz et al. Murphy et al. Pekkarinen & Mustajoki Stalonas et al. Stunkard & Penik Wadden & Frey Wadden et al. Walsh & Flynn Weight change (kg) Mean change from baseline to end of diet (kg) Mean change from baseline to follow-up (kg) Follow up range from 4 to 7 years Mann et al. Am Psychol 2007;62:220 33
18 Physiological responses to weight loss favour weight regain 1 2 Energy intake Resting energy expenditure Hunger Desire to eat Leptin Adipose tissue Insulin GLP-1, CCK, PYY, Ghrelin Pancreas Gut CCK, cholecystokinin; GLP-1, glucagon-like peptide-1; PYY, peptide YY 1. Schwartz et al. Obes Rev 2010;11:531 47; 2. Sumithran et al. N Engl J Med 2011;365:
19 Pharmacotherapy in addition to diet and exercise can help patients achieve clinically relevant weight loss Pharmacotherapy alone Lifestyle modification alone Weight change (kg) Pharmacotherapy + brief lifestyle modification Combined therapy Weeks Data are mean ± SE Pharmacotherapy: sibutramine; Pharmacotherapy alone: Patients received a daily dose of 15 mg/day; Lifestyle modification alone: Patients attended 30 lifestyle counselling sessions; Pharmacotherapy + brief therapy: Patients were given sibutramine and received brief lifestyle counselling; Combined therapy: Patients received sibutramine and attended 30 lifestyle counselling sessions. Wadden et al. N Engl J Med 2005;353:
20 Unmet pharmacological need for obesity treatment Lifestyle modification 1 Pharmacotherapy plus lifestyle modification 1 Gastric band 2 Gastric sleeve 2 Gastric bypass Weight loss (%) 1. Jensen et al. Circulation 2014;129(25 Suppl 2):S102 38; 3. Courcoulas et al. JAMA 2013;310: ; 3. Obesity Drug Outcome Measures: A Consensus Report of Considerations Regarding Pharmacologic Intervention. Available at: (accessed 15 February 2016)
21 Clinical management of obesity AHA/ACC/TOS guidelines Guidance centred around weight loss as means of CV risk Diet and exercise remain cornerstone of weight loss interventions Participation in a long-term ( 1 year) comprehensive weight loss maintenance programme is strongly recommended Surgery may be appropriate after diet and exercise and pharmacotherapy failure AHA, American Heart Association; ACC, American College of Cardiology; CV, cardiovascular; TOS, The Obesity Society Jensen et al. J Am Coll Cardiol 2014;63(25 Pt B):
22 GLP-1 is a physiological regulator of appetite and energy intake Obesity is a chronic disease requiring long-term management GLP-1 is a physiological regulator of appetite and energy intake Liraglutide, a once-daily human GLP-1 analogue, reduces appetite and energy intake Efficacy and safety of liraglutide 3.0 mg in weight management GLP-1, glucagon-like peptide-1
23 GLP-1 is released in response to food intake 50 Meal Meal Meal GLP-1 n=6 Plasma GLP-1 concentration (pmol/l) Time (h) 24 Adapted from: Orskov et al. Scand J Gastroenterol 1996;31:665 70
24 Metabolic effects of GLP-1 Appetite 1 Satiety Fullness Hunger Prospective food consumption Energy intake Glucose regulation 2 (Glucose-dependent) Insulin secretion Glucagon secretion Gastric effects 3,4 Gastric acid Gastric emptying GLP-1, glucagon-like peptide-1 1. Flint et al. J Clin Invest 1998;101:515 20; 2. Nauck et al. Diabetologia 1993;36:741 4; 3. O'Halloran et al. J Endocrinol 1990;126:169 73; 4. Nauck et al. Am J Physiol 1997;273:E981 8
25 Liraglutide, a once-daily human GLP-1 analogue, reduces appetite and energy intake Obesity is a chronic disease requiring long-term management GLP-1 is a physiological regulator of appetite and energy intake Liraglutide, a once-daily human GLP-1 analogue, reduces appetite and energy intake Efficacy and safety of liraglutide 3.0 mg in weight management GLP-1, glucagon-like peptide-1
26 Liraglutide is a once-daily, human GLP-1 analogue His Ala Glu Gly Thr Phe Thr Ser Asp Val Human endogenous GLP-1 Lys Glu Ala Ala Gln Gly Glu Leu Tyr Ser Ser Phe Ile Ala Trp Leu Val Lys Gly Arg Gly C-16 fatty acid (palmitoyl) T ½ = ~2 mins His Ala Glu Gly Thr Phe Thr Ser Glu Lys Glu Ala Ala Gln Gly Glu Phe Ile Ala Trp Leu Val Arg Leu Tyr Gly Arg Asp Val Ser Ser Gly Liraglutide 97% amino acid homology to human GLP-1; improved PK: albumin binding through acylation; heptamer formation Slow absorption from subcutis Resistant to DPP-4 Long plasma half-life (T ½ =13 h) DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; PK, pharmacokinetics; T ½, plasma half-life Knudsen et al. J Med Chem 2000;43:1664 9; Degn et al. Diabetes 2004;53:
27 Liraglutide 3.0 mg influences all dimensions of appetite Satiety (mm) 100 Satiety Fullness (mm) 100 Fullness Liraglutide 3.0 mg 80 Placebo Hunger (mm) 100 Hunger Time (min) Time (min) Appetite ratings were assessed by visual analog scale. Data are presented as mean ± standard error. PFC, prospective food consumption Adapted from: van Can et al. Int J Obes 2014;38: PFC (mm) 100 Prospective food consumption
28 Efficacy and safety of liraglutide 3.0 mg in weight management Obesity is a chronic disease requiring long-term management GLP-1 is a physiological regulator of appetite and energy intake Liraglutide, a once-daily human GLP-1 analogue, reduces appetite and energy intake Efficacy and safety of liraglutide 3.0 mg in weight management GLP-1, glucagon-like peptide-1
29 SCALE Phase 3a clinical trial programme Liraglutide 1.8 mg is not approved for weight management SCALE Obesity and Prediabetes (1839) 1 SCALE Maintenance (1923) 3 Weight management & delayed onset of diabetes Liraglutide 3.0 mg n=2487 Placebo n=1244 Prevention of weight regain Liraglutide 3.0 mg n=212 Placebo n=210 SCALE Diabetes (1922) 2 SCALE Sleep Apnoea (3970) 4 Weight management in type 2 diabetes Liraglutide 3.0 mg n=423 Liraglutide 1.8 mg n=211 Placebo n=212 Effect of liraglutide in subjects with obesity and moderate to severe OSA Liraglutide 3.0 mg n=180 Placebo n=179 *SCALE, Sleep apnoea 3970 trial BMI 30 kg/m 2 plus co-morbidities; BMI, body mass index; OSA, obstructive sleep apnoea; SCALE, Satiety and Clinical Adiposity Liraglutide Evidence in individuals with and without diabetes 1. Pi-Sunyer et al. N Engl J Med 2015;373:11 22; 2. Davies et al. JAMA 2015;314:687 99; 3. Wadden et al. Int J Obes (Lond) 2013;37: ; 4. Blackman et al. Int J Obes (Lond). 2016;40:1310-9
30 Trial design: SCALE Obesity and Prediabetes Liraglutide 3.0 mg in weight management (56 weeks) 3731 participants 18 years Stable BW BMI 30 kg/m 2 or 27 kg/m 2 + comorbidities Without prediabetes With prediabetes 1 Liraglutide 3.0 mg (n=959) Placebo (n=487) Liraglutide 3.0 mg (n=1528) Placebo (n=757) Lifestyle intervention: -500 kcal/day diet min/week physical activity Dose escalation 0 4 weeks Treatment duration 52 weeks 12 weeks 2-week FU Trial information June 2011 to March 2013 Randomised controlled double-blind study 191 sites in 27 countries Duration: 56 weeks (with prediabetes), 68 weeks (without prediabetes) Randomisation (2:1) Re-randomisation (1:1) EOT Trial objective Efficacy and safety of liraglutide 3.0 mg, as adjunct to D&E, in participants with obesity or overweight plus comorbidities, without diabetes Key endpoints Three co-primary: BW change, 5% or 10% BW loss Secondary: Changes from baseline in BMI, WC, glycaemic control variables, cardiometabolic risk factors, and HRQoL 1. ADA. Diabetes Care 2010;33(Suppl. 1):S11 61 BW, body weight; D&E, diet and exercise; EOT, end of treatment; FU, follow-up; HRQoL, health-related quality of life; WC, waist circumference Pi-Sunyer et al. N Engl J Med 2015;373:11 22
31 Change in body weight (%) 0 56 weeks Mean baseline weight: 106 kg 0 Liraglutide 3.0 mg Observed mean LOCF Placebo Observed mean LOCF Change in weight (%) % -3.5% -8.0% -9.2% p< Week FAS, fasting visit data only. Line graphs are observed means (±SE). Statistical analysis is ANCOVA. FAS, full analysis set; LOCF, last observation carried forward; SE, standard error Pi-Sunyer et al. Diabetologia 2014;57(Suppl. 1): Abstract 73-OR
32 Liraglutide 3mg locally approved insert leaflet version STF Dec 2017
33 Individuals with prediabetes at week 56 In individuals with normoglycaemia at screening Individuals with prediabetes (%) Liraglutide 3.0 mg p< Placebo 20.7 At screening 56 weeks FAS LOCF. Graphs are observed proportions. Statistical analysis is logistic regression. In this analysis prediabetes includes subjects with transient and confirmed type 2 diabetes. EOR, estimated odds ratio; FAS, full analysis set; LOCF, last observation carried forward Adapted from Pi-Sunyer et al. N Engl J Med 2015;373:11 22
34 Individuals with prediabetes at week 56 In individuals with prediabetes at screening Individuals with prediabetes (%) Liraglutide 3.0 mg p< Placebo 67.3 At screening 56 weeks FAS LOCF. Graphs are observed proportions. Statistical analysis is logistic regression. In this analysis prediabetes includes subjects with transient and confirmed type 2 diabetes. EOR, estimated odds ratio; FAS, full analysis set; LOCF, last observation carried forward Adapted from Pi-Sunyer et al. N Engl J Med 2015;373:11 22
35 Changes in blood pressure and pulse 0 56 weeks Mean baseline SBP: 123 mmhg Mean baseline DBP: 79 mmhg Mean baseline pulse: 71 bpm Change in SBP (mmhg) Change in DBP (mmhg) Change in pulse (bpm) Liraglutide 3.0 mg Observed mean LOCF Placebo Observed mean LOCF Week * * 2.5* 0.1 FAS, LOCF (blood pressure); SAS, LOCF (pulse). Data are observed means (±SE) of all participants attending each visit. Statistical analyses are ANCOVA. *p< ANCOVA, analysis of covariance; bpm, beats per minute; DBP, diastolic blood pressure; FAS, full analysis set; LOCF, last observation carried forward; SAS, safety analysis set; SBP, systolic blood pressure; SE, standard error Pi-Sunyer et al. N Engl J Med 2015;373:11 22
36 Change in fasting lipids 0 56 weeks Liraglutide 3.0 mg Placebo Change from baseline (%) ETD -2.3 (-3.3, -1.3) P< Total cholesterol ETD -2.4 (-4.0, -0.9) P=0.002 LDL cholesterol ETD 1.9 (0.7, 3.0) P=0.001 HDL cholesterol ETD -9.1 (-11.4, -6.8) P< VLDL cholesterol ETD -3.9 (-5.2, -2.5) P< Non-HDL cholesterol ETD -9.3 (-11.5, -7.0) P< Triglycerides ETD -4.2 (-7.3, -0.9) P=0.01 Free fatty acids FAS, LOCF. Data are based on observed geometric means. Statistical analysis is ANCOVA. ETD, estimated treatment difference (95% CI); FAS, full analysis set; LOCF, last observation carried forward Pi-Sunyer et al. N Engl J Med 2015;373:11 22
37 Change in cardiovascular biomarkers 0 56 weeks Liraglutide 3.0 mg Placebo Change from baseline (%) ETD (-34.3, -26.5) P< ETD 8.5 (5.5, 11.6) P<0.001 ETD 0.5 (-1.2, 2.1) P= ETD -3.6 (-10.1, 3.4) P=0.31 hscrp Adiponectin Fibrinogen Urinary albumin: creatinine ratio 14.9 FAS, LOCF. Data are based on observed geometric means. Statistical analysis is ANCOVA. Data for PAI-1 not available. Data are shown as % change from baseline. Units of measure were hscrp (mg/l); Adiponectin (mg/l); Fibrinogen (g/l); Urinary albumin: creatinine ratio (mg/mol). FAS, full analysis set; ETD, estimated treatment difference (95% CI); LOCF, last observation carried forward Pi-Sunyer et al. N Engl J Med 2015;373:11 22
38 Summary of IWQOL-Lite 0 56 weeks Increase = Improvement Liraglutide 3.0 mg Placebo 15 * * Mean change (score) 10 5 * * * * 0 Total Score Physical Function Self- Esteem Sexual Life Public Distress Work FAS LOCF. Bar graph is observed mean change from baseline. Statistical analysis is ANCOVA. *p<0.01 FAS, full analysis set; IWQOL-Lite, Impact of weight on quality of life-lite questionnaire; LOCF, last observation carried forward Pi-Sunyer et al. N Engl J Med 2015;373:11 22
39 Proportion of individuals with nausea 0 56 weeks Individuals (%) Liraglutide 3.0 mg Placebo Proportion of patients reporting nausea at: Week 4: 24.7% (liraglutide) vs. 5.4% (placebo) Week 8: 14.7% (liraglutide) vs. 3.2% (placebo) Week 56: 5.5% (liraglutide) vs. 1.7% (placebo) Week Safety analysis set Pi-Sunyer et al. N Engl J Med 2015;373:11 22
40 Weight loss with and without nausea/vomiting 0 56 weeks N 0 With nausea/vomiting Without nausea/vomiting Liraglutide 3.0 mg Placebo Weight change (%) ETD -5.4% ETD -5.5% p=0.81 for interaction between nausea/vomiting and treatment effect Least square means (± standard error); LOCF at end-of-treatment (56 weeks); ETD, estimated treatment difference; LOCF, last observation carried forward; N, number of subjects contributing to analysis Lean et al. AACE 2015; Poster 611. Abstract available here.
41 SCALE Obesity and Prediabetes (56 weeks) Summary Liraglutide 3.0 mg once-daily, as an adjunct to diet and exercise, was associated with clinically meaningful weight loss in individuals with obesity or with overweight and comorbidities Liraglutide 3.0 mg was also associated with improvements in glycaemia, cardiometabolic risk factors and health-related quality of life Safety profile was generally consistent with that of previous clinical trials with liraglutide 3.0 mg and liraglutide 1.8 mg in individuals with T2D Liraglutide 3.0 mg was generally well tolerated with nausea, diarrhoea and constipation being the most commonly reported adverse events CV, cardiovascular; HRQoL, health-related quality of life; T2D, type 2 diabetes Pi-Sunyer et al. New Engl J Med 2015;373:11 22
42 Trial design: SCALE Obesity and Prediabetes extension Liraglutide 3.0 mg in weight management (160 weeks) Inclusion criteria: 18 years Stable BW BMI 30 kg/m 2 or 27 kg/m 2 + comorbidities Without prediabetes With prediabetes 1 Liraglutide 3.0 mg Placebo Liraglutide 3.0 mg (n=1505) Placebo (n=749) Trial information June 2011 to March 2015 Randomised controlled double-blind study 191 sites in 27 countries Lifestyle intervention: -500 kcal/day diet min/week physical activity Dose escalation 0 4 weeks Treatment duration 156 weeks 12-week off-drug FU Randomisation (2:1) Trial objective Efficacy of liraglutide 3.0 mg (after 160 weeks of treatment) in delaying the onset of T2DM in participants with obesity or overweight with comorbidities, and diagnosed with prediabetes at screening 160 weeks End of trial Key endpoints Primary: time to onset of T2DM at 160 weeks Secondary: weight measures, glycaemic control variables, cardiometabolic risk factors, HRQoL, safety and tolerability 1. ADA. Diabetes Care 2010;33(Suppl. 1):S62 9 BW, body weight; D&E, diet and exercise; FU, follow-up; HRQoL, health-related quality of life; T2DM, type 2 diabetes mellitus le Roux et al. Lancet 2017;389:
43 Participants diagnosed with T2DM over time Kaplan Meier plot: weeks 12 Liraglutide 3.0 mg Off drug follow up Placebo Off drug follow up Placebo: 11% Liraglutide 3.0 mg: 3% Participants (%) n= n= Week Full analysis set. Numbers in the figure correspond to the accumulated number of diagnosed participants T2DM, type 2 diabetes mellitus le Roux et al. Lancet 2017;389:
44 Change in body weight (%) weeks Change in weight (%) n= n= Liraglutide 3.0 mg Off-drug follow-up Observed mean LOCF -3.5% -9.2% Placebo Off-drug follow-up Observed mean LOCF Week -3.4% -8.5% -1.9% -6.1% ETD at week 160: 4.3% [ 4.9; 3.7] p< % -7.1% % -5.2% Full analysis set, fasting visit data only. Line graphs are observed means (±SE) LOCF, last observation carried forward; SE, standard error le Roux et al. Lancet 2017;389:
45 Change in SBP (mmhg) weeks Change in SBP (mmhg) n= n= Liraglutide 3.0 mg Off drug follow up Observed mean LOCF Week Placebo Off drug follow up Observed mean LOCF ETD at week 160: -2.8 [-3.8;-1.8] p< Full analysis set. Line graphs are observed means (±SE) LOCF, last observation carried forward; SBP, systolic blood pressure; SE, standard error le Roux et al. Lancet 2017;389:
46 Summary of IWQoL-Lite Mean change from baseline at 160 weeks Liraglutide 3.0 mg Placebo Increase = Improvement 20 Score mean change * * * * * * 0 Physical function Selfesteem Sexual life Public distress Work Total score Minimal important difference: for total score 1 Full analysis set, last observation carried forward. Bar graph is observed means. Statistical analysis is ANCOVA. *p< Crosby et al. J Clin Epidemiol 2004;57: ANCOVA, analysis of covariance; IWQoL-Lite, Impact of weight on quality of life-lite questionnaire le Roux et al. Lancet 2017;389:
47 Conclusions Three years of treatment with once-daily subcutaneous liraglutide 3.0 mg, as an adjunct to a life style modification, reduced the risk of T2DM in individuals with overweight or obesity and prediabetes, and promoted greater weight loss and improvements in glycaemic control and cardiometabolic risk factors compared with placebo Liraglutide 3.0 mg, as a GLP-1RA, has also direct glucose-dependent effects on insulin secretion in addition to weight-loss mediated reduction in insulin resistance Liraglutide 3.0 mg is generally well tolerated. GLP-1RA, glucagon-like peptide-1 receptor agonist; T2DM, type 2 diabetes mellitus le Roux et al. Lancet 2017;389:
48 Liraglutide 1.8 mg is not approved for weight management Label update!! Liraglutide 3mg is the only anti-obesity treatment to include CV benefit data (significant decrease in CV death) in its label (LEADER study) From liraglutide 1.8 mg T2D trial data to liraglutide 3.0 mg for weight management Overlapping body weights Overlapping exposure T2D trials (doses up to 1.8 mg) Weight management trials (doses up to 3.0 mg) Proportion Proportion Red line = maximum exposure in T2D The LEADER trial, characterizes the CV risk of liraglutide, (1.8 mg) dose Body weight (kg) AUC (mg.h/l) AUC, area under the curve Novo Nordisk Briefing Document: Liraglutide 3.0 mg for weight management NDA Click Here.
49 Liraglutide dosing and titration 1. Liraglutide locally approved insert leaflet version STF Dec 2017
50 Summary Obesity is a chronic challenging disease with multiple comorbidities. 5-10% weight loss significantly improves most comorbidities (risk of T2D, CV mortality, blood lipids, BP, OSA, NAFLD and quality of life) Liraglutide 3mg safely provides significant weight loss and helps maintain weight loss on the long term: Assessment should be done after 12 weeks on the 3 mg dose (16 weeks of treatment if the titration phase takes 4 weeks) to decide if the patient is a responder (weight loss 5%) or not (less than 5% weight loss) Responders are predicted to reach a weight loss of 11.2% at 56 weeks Liraglutide 3mg provides benefits beyond weight loss: On glucose control with a 69% regression to normoglycemia in patients with prediabetes, and 80% risk reduction of developing type 2 diabetes. Is the only anti-obesity treatment to include CV benefit data
51 THE END THANK YOU
Dr Matthew Coghlan Novo Nordisk
Dr Matthew Coghlan Novo Nordisk Preventing diabetes and its complications Matthew Coghlan PhD Senior Director Search & Evaluation Global Drug Discovery Novo Nordisk A/S Obesity rates worldwide are increasing
More informationDr. Shahebina Walji MD. Clinical Lecturer, University of Calgary Medical Director, Calgary Weight Management Centre
Dr. Shahebina Walji MD Clinical Lecturer, University of Calgary Medical Director, Calgary Weight Management Centre info@cwmc.ca 403.272.2962 Impact of obesity on Canadians Obesity as a chronic medical
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationBariatric surgery: Impact on Co-morbidities and Weight Loss Expectations ALIYAH KANJI, MD FRCSC MIS AND BARIATRIC SURGERY SEPTEMBER 22, 2018
Bariatric surgery: Impact on Co-morbidities and Weight Loss Expectations ALIYAH KANJI, MD FRCSC MIS AND BARIATRIC SURGERY SEPTEMBER 22, 2018 Disclosures None Objectives Review expected weight loss from
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase
More informationObesity D R. A I S H A H A L I E K H Z A I M Y
Obesity D R. A I S H A H A L I E K H Z A I M Y Objectives Definition Pathogenesis of obesity Factors predisposing to obesity Complications of obesity Assessment and screening of obesity Management of obesity
More informationEffective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.
Effective Interventions in the Clinical Setting: Engaging and Empowering Patients Michael J. Bloch, M.D. Doina Kulick, M.D. UNIVERSITY OF NEVADA SCHOOL of MEDICINE Sept. 8, 2011 Reality check: What could
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More information3/11/2019. Debate: A Conversation on Weight Management and Health at Every Size. Defining Obesity. Obesity: In the top three global social burdens
Foundational Concepts Debate: A Conversation on Weight Management and Health at Every Size Robert F. Kushner, MD, MS Professor of Medicine Northwestern University Feinberg School of Medicine Director,
More informationManagement of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.
Medical Management of Obesity Ben O Donnell, MD 1 Objectives Background Impact and scope of Obesity Control of Energy Homeostasis Methods of treatment Medications 2 O'Donnell 1 Impact of Obesity According
More informationUnderstanding the Biology of Weight and Weight Regain to Assist those Challenged with Obesity
Understanding the Biology of Weight and Weight Regain to Assist those Challenged with Obesity Diana L Lawlor MN RN-NP Oct 2017 Our World Has Changed Our world has changed Energy In Vs Energy Out
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationPharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management. Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018
Pharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018 COI Faculty: Renuca Modi, MD, CCFP Diplomate of the
More informationOBESITY:Pharmacotherapy Vs Surgery
OBESITY:Pharmacotherapy Vs Surgery Dr. Ranajit Sen Chowdhury Associate Professor Department of Medicine Sir Salimullah Medical College & Mitford Hospital. 1 Historical Perspective Paleolithic Era > 25,000
More informationBariatric Surgery: Indications and Ethical Concerns
Bariatric Surgery: Indications and Ethical Concerns Ramzi Alami, M.D. F.A.C.S Assistant Professor of Surgery American University of Beirut Medical Center Beirut, Lebanon Nothing to Disclose Determined
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationDisclosures OBESITY. Overview. Obesity: Definition. Prevalence of Obesity is Rising. Obesity as a Risk Factor. None
Disclosures None OBESITY Florencia Halperin, M.D. Medical Director, Program for Management Brigham and Women s Hospital Instructor in Medicine, Harvard Medical School Overview Obesity: Definition Definition
More informationInjectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
More informationAccess to Proven Therapies
Access to Proven Therapies Obesity is a life-threatening disease affecting 34% of adults in the U.S. Between 2000 and 2005, obesity increased by 24%, morbid obesity by 50%, and super obesity by 75%. 18%
More informationObesity: Pharmacologic and Surgical Management
Obesity: Pharmacologic and Surgical Management ADRIENNE YOUDIM, MD, FACP ASSOCIATE PROFESSOR OF MEDICINE, UCLA ASSISTANT PROFESSOR OF MEDICINE, CEDARS SINAI MEDICAL CENTER JANUARY 2018 Defining Obesity
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationThe New Trend of Anti-Obesity Drug
2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity
More informationOBESITY IN PRIMARY CARE
OBESITY IN PRIMARY CARE Obesity- definition Is a chronic disease In ICD 10 E66 Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. Obesity is a leading
More informationEmpower Preventive Medicine. Timothy J. McCormick, DO, MPH 4221 Baymeadows Suite 6 Jacksonville, FL
Empower Preventive Medicine Timothy J. McCormick, DO, MPH 4221 Baymeadows Suite 6 Jacksonville, FL 32217 904-367-4005 Drtim@emprevmed.com Obesity Medicine Old paradigm: Obesity was a matter of willpower,
More informationChapter 12. Ingestive Behavior
Chapter 12 Ingestive Behavior Drinking a. fluid compartments b. osmometric thirst c. volumetric thirst Eating a. energy sources b. starting a meal c. stopping a meal d. eating disordersd Drinking a. fluid
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationScience of Obesity (I-2.28)
Science of Obesity (I-2.28) Dr Noha Nooh Lasheen Lecturer of Physiology Date :16 / 10 / 2016 Objectives By the end of this lecture, the student should be able to: Define energy, energy balance and obesity.
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationOverview of Management of Obesity
Overview of Management of Obesity Srividya Kidambi, MD, MS Division of Endocrinology, Metabolism, and Clinical Nutrition Medical College of Wisconsin, Milwaukee, WI I have nothing to disclose. Objectives
More informationThe Implications of Obesity as a Disease
AGA Technology Workshop The Implications of Obesity as a Disease Lee M. Kaplan, MD, PhD Obesity, Metabolism & Nutrition Institute Massachusetts General Hospital Harvard Medical School LMKaplan@partners.org
More information8/27/2012. Mississippi s Big Problem. An Epidemic Now Reaching Our Children. What Can We Do?
Mississippi s Big Problem. An Epidemic Now Reaching Our Children What Can We Do? Richard D. deshazo, MD Billy S. Guyton Distinguished Professor Professor of Medicine & Pediatrics University of Mississippi
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationViriato Fiallo, MD Ursula McMillian, MD
Viriato Fiallo, MD Ursula McMillian, MD Objectives Define obesity and effects on society and healthcare Define bariatric surgery Discuss recent medical management versus surgery research Evaluate different
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationAn Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD Sanford I. Weill Professor of Metabolic Research Director of the Comprehensive Weight Control Program Weill Cornell Medical College
More informationObesity: The Role of Pharmacotherapy The Annual Women s & Children s Health Update Saturday 17th February 2018 Benefits of modest weight loss 3-10%
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
More informationDIABETES. A growing problem
DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGut hormones KHATTAB
Gut hormones PROF:ABD ALHAFIZ HASSAN KHATTAB Gut as an endocrine gland The talk will cover the following : Historical background. Why this subject is chosen. Gastro-intestinal hormones and their function.
More informationWhat Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
More informationOVERWEIGHT AND OBESITY. Dharma Lindarto Div. Endokrin-Metabolik Departemen Penyakit Dalam FK USU/RSUP H Adam Malik Medan.
OVERWEIGHT AND OBESITY Dharma Lindarto Div. Endokrin-Metabolik Departemen Penyakit Dalam FK USU/RSUP H Adam Malik Medan. Defining obesity Obesity - an excessive accumulation of body fat sufficient to impair
More informationThe US FDA, EMA and our TGA use these cutpoints in assessing drug efficacy. Disclosures: Professor John B Dixon
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
More informationClinical Staging for Obesity. Raj Padwal Clinical Pharmacology and General Internal Medicine University of Alberta
Clinical Staging for Obesity Raj Padwal Clinical Pharmacology and General Internal Medicine University of Alberta Disclosures Funding: CIHR, Heart and Stroke Foundation of Canada, University Hospital Foundation.
More informationPage 2: Baker IDI. Page 4: Baker IDI. Global & Regional Obesity. High income English speaking Light Blue. Global & Regional Severe obesity
Metabolic Update Patients selection and choice of procedure Professor John B Dixon MBBS, FRACGP, FRCP Edin, PhD NHMRC Senior Research Fellow Head of Clinical Obesity Research, Baker IDI Heart and Diabetes
More informationBariatric Surgery MM /11/2001. HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient; Inpatient
Bariatric Surgery Policy Number: Original Effective Date: MM.06.003 09/11/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient;
More information«Πατσζαρκία και Καρδιαγγειακή Νόζος»
«Πατσζαρκία και Καρδιαγγειακή Νόζος» Δημήτρης Π. Παπαδόπουλος-FESC Clinical Assist. Professor George Washington University USA Επιμελητής Καρδιολογικής Κλινικής Π.Γ.Ν.Α. «ΛΑΪΚΟ» Υπεύθυνος Αντιυπερτασικού
More informationEnergy Balance Equation
Energy Balance Equation Intake Expenditure Hunger Satiety Nutrient Absorption Metabolic Rate Thermogenesis Activity Eat to Live! Live to Eat! EAT TO LIVE Intake = Expenditure Weight Stable LIVE TO EAT
More informationBariatric Surgery in NASH Results, indications and contra-indications
Bariatric Surgery in NASH Results, indications and contra-indications Guillaume Lassailly CHRU de Lille Conflit of interest No conflict of interest related to this lecture Contract with: Novartis Gilead
More informationDisclosures. Obesity and Its Challenges: Outline. Outline 5/2/2013. Lan Vu, MD Division of Pediatric Surgery Department of Surgery
Obesity and Its Challenges: Bariatric Surgery: Why or Why Not I have nothing to disclose Disclosures Lan Vu, MD Division of Pediatric Surgery Department of Surgery Outline Growing obesity epidemic Not
More informationUnderstanding Obesity: The Causes, Effects, and Treatment Options
Understanding Obesity: The Causes, Effects, and Treatment Options Jeffrey Sicat, MD, FACE Virginia Association of Clinical Nurse Specialists September 29, 2017 Objectives By the end of this discussion,
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More information1 Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. Endocr Pract. 2012;18: Depression. Cancer. Gallbladder Disease
Percent 4 3 2 1 Obese Overweight Extremely obese Note: Age-adjusted by the direct method to the year 2 US Bureau of the Census using age groups 2 39, 4 59, and 6 74 years. Pregnant females excluded. Overweight
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial
More informationDepression, anxiety, and obesity
Depression, anxiety, and obesity 5As Team Learning modules Depression and anxiety are two prevalent mood disorders that affect Canadians, with as many as 40-70% of overweight/obese individuals at high
More informationDeveloping nations vs. developed nations Availability of food contributes to overweight and obesity
KNH 406 1 Developing nations vs. developed nations Availability of food contributes to overweight and obesity Intake Measured in kilojoules (kj) or kilocalories (kcal) - food energy Determined by bomb
More informationGetting Ahead of the Curve in the Trouble with Fat
Getting Ahead of the Curve in the Trouble with Fat Zhaoping Li, M.D., Ph.D. Professor of Medicine David Geffen School of Medicine, UCLA VA Greater Los Angeles Health Care System Obesity Pandemic Predicted
More informationObesity in Children. JC Opperman
Obesity in Children JC Opperman Definition The child too heavy for height or length Obvious on inspection 10 to 20% over desirable weight = overweight More than 20% = obese Use percentile charts for the
More informationWhat is Metabolic About Metabolic Surgery? The New ADA Recommendations
What is Metabolic About Metabolic Surgery? The New ADA Recommendations Obesity Symposium September 16, 2017 Timothy Howland, MD Lourdes Endocrinology Bariatric from the Greek root bar- ("weight" as in
More informationManaging Obesity as a Disease. Disclosure. Objectives
Managing Obesity as a Disease Ji Hyun Chun (CJ), PA-C, BC-ADM OptumCare Medical Group: Endocrinology, Irvine, CA President, American Society of Endocrine PAs none Disclosure Objectives Recognize obesity
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationWhere are we with Incretin Based Therapies for the Treatment of Diabetes?
Where are we with Incretin Based Therapies for the Treatment of Diabetes? Jens Juul Holst, NNF Center for Basic Metabolic Research Department of Biomedical Sciences Panum Institute, University of Copenhagen,
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationFaculty/Presenter Disclosure
Weight loss & Obesity WHAT S NEW & EXCITING? Tina Korownyk Dept of Family Medicine, UofA Faculty/Presenter Disclosure Faculty/Presenter: Tina Korownyk Relationships with commercial interests: None 1 Drowning
More informationOBESITY OVERVIEW. Natsurang Chongkrairatanakul, MD
OBESITY OVERVIEW Natsurang Chongkrairatanakul, MD Diplomat of American Board of Obesity Medicine Assistant Professor of Internal Medicine, Endocrinology Diabetes and Nutrition Froedtert & Medical College
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationMeccanismi fisiopatologici e trattamento dei disturbi metabolici in soggetti affetti da disturbo mentale grave
Meccanismi fisiopatologici e trattamento dei disturbi metabolici in soggetti affetti da disturbo mentale grave Francesco Bartoli, MD, PhD Università degli Studi di Milano Bicocca Ospedale San Gerardo di
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationObesity: from epidemiology to treatment Entwicklung der Adipositas und Epidemiology, definition and des Diabetes in Europa diagnosis of obesities
Obesity: from epidemiology to treatment Entwicklung der Adipositas und Epidemiology, definition and des Diabetes in Europa diagnosis of obesities Hermann Toplak, Präsident ÖDG &EASO Hermann Toplak, President
More information6/23/2011. Bariatric Surgery: What the Primary Care Provider Should Know. Case Presentation: Rachelle
Bariatric Surgery: What the Primary Care Provider Should Know 2,000 B.C. 2,000 A.D. Case Presentation: Rachelle 35 year-old woman with morbid obesity. 5 1 236 lbs BMI 44.5 PMHx: mild depression obstructive
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 15 November 2007 Doc. Ref. EMEA/CHMP/EWP/517497/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL EVALUATION OF MEDICINAL PRODUCTS USED
More informationBariatric surgery as a model for obesity research. Nick Finer BSc, FRCP, FAfN University College London UK
Bariatric surgery as a model for obesity research Nick Finer BSc, FRCP, FAfN University College London UK Defining the problem - what do we know and what has been achieved (greatest achievements)? Obesity
More informationSue Cummings, MS, RD
Starting Principles: Causes of Obesity Obesity is a chronic disease that is: Dietary Causes of Weight Regain SUE CUMMINGS, MS, RD SCUMMINGS1@PARTNERS.ORG both biopsychosocially complex in its origins and
More informationBariatric Surgery: A Cost-effective Treatment of Obesity?
Bariatric Surgery: A Cost-effective Treatment of Obesity? Shaneeta M. Johnson MD FACS FASMBS 2018 NMA Professional Development Seminar Congressional Black Caucus Foundation Annual Legislative Conference
More informationObjectives. Define satiety and satiation Summarize the satiety cascade Describe potential dietary interventions aimed at improving satiety
Foods that Fill Monica Esquivel PhD RDN Assistant Professor, Dietetics Program Director Department of Human Nutrition, Food and Animal Sciences November 8, 2017 Objectives Define satiety and satiation
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationOBESITY: The Growing Epidemic and its Medical Impact
OBESITY: The Growing Epidemic and its Medical Impact Ray Plodkowski, MD Co-Chief, Chief, of Division of Medical Nutrition, University of Nevada School of Medicine. Chief, Endocrinology & Metabolism, Sachiko
More informationGlycemic control what can be achieved with life-style and when and how to use pharmacological agents?
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key
More informationTable S2: Anthropometric, clinical, cardiovascular and appetite outcome changes over 8 weeks (baseline-week 8) by snack group
Table S1: Nutrient composition of cracker and almond snacks Cracker* Almond** Weight, g 77.5 g (5 sheets) 56.7 g (2 oz.) Energy, kcal 338 364 Carbohydrate, g (kcal) 62.5 12.6 Dietary fiber, g 2.5 8.1 Protein,
More informationMetabolically healthy obesity and NAFLD
News & Views Metabolically healthy obesity and NAFLD Giovanni Targher and Christopher D. Byrne Giovanni Targher is at the Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University
More informationPart 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.
Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes Stephen D. Sisson MD Objectives To review dietary recommendations in the following conditions: Obesity Hypertension Diabetes
More informationDigestion: Endocrinology of Appetite
Digestion: Endocrinology of Dr. Ritamarie Loscalzo Medical Disclaimer: The information in this presentation is not intended to replace a one on one relationship with a qualified health care professional
More informationAppetite control, Food Choice and Physical Activity Implications for Energy Balance and Weight Control
Appetite control, Food Choice and Physical Activity Implications for Energy Balance and Weight Control John Blundell Chair of PsychoBiology University of Leeds Energy Balance and Active Living: Perspectives
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationLESSON 3.3 WORKBOOK. How do we decide when and how much to eat?
Appetite The psychological desire to eat, driven by feelings of pleasure from the brain. Hunger The biological or physiological need to eat, caused by a release of hormones from the digestive tract. LESSON
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationWHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH?
WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? Helena Cortez-Pinto Laboratório de Nutrição, FML, Serviço de Gastrenterologia, Hospital St Maria, Lisboa, Portugal EASL Governing Board:
More informationLearning Objectives 11/8/2014. Obesity: Strategies to Tackle the Epidemic MA ACP Annual Scientific Meeting 1. Body Mass Index Calculation
Fatima Cody Stanford, MD, MPH Obesity Medicine & Nutrition Massachusetts General Hospital Harvard Medical School Learning Objectives Review the prevalence of obesity in the USA Outline pathogenesis and
More informationObesity and Anaesthesia. Western General Hospital. Friday 10 th March 2006.
Obesity and Anaesthesia Western General Hospital. Friday 10 th March 2006. Obesity: Topics Definition Incidence. Pathophysiology Pharmacokinetics. Anaesthesia. Bariatric Surgery. Definition 1 Body Mass
More information10/28/11. Bariatric Surgery: What the Primary Care Provider Should Know. Case Presentation: Rachelle
Bariatric Surgery: What the Primary Care Provider Should Know 2,000 B.C. 2,000 A.D. Case Presentation: Rachelle 35 year-old woman with morbid obesity. 5 1 236 lbs BMI 44.5 PMHx: mild depression obstructive
More informationDiabetes Head To Toe May 31, Obesity in Canada. Six million Canadians are living with obesity
Medical & Surgical Options for the Bariatric Patient Michelle Mountain, RD, B.Sc Obesity in Canada 1 in 5 adults are obese Six million Canadians are living with obesity 1 in 10 children have clinical obesity
More informationPage 2: Baker IDI. Page 4: Baker IDI. Global & Regional Obesity. High income English speaking Light Blue. Global & Regional Severe obesity
Metabolic Surgery Update Patients selection and choice of procedure Professor John B Dixon MBBS, FRACGP, FRCP Edin, PhD NHMRC Senior Research Fellow Head of Clinical Obesity Research, Baker IDI Heart and
More informationImpact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients
2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type
More information